| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 1914 |
| 1 | PREDNISONE | 1855 |
| 2 | CYCLOPHOSPHAMIDE | 1689 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 1689 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 1689 |
| 5 | DEXAMETHASONE | 1609 |
| 6 | DEXAMETHASONE 1.5 MG | 1609 |
| 7 | CARBOPLATIN | 1532 |
| 8 | RITUXIMAB | 1414 |
| 9 | METHOTREXATE SODIUM | 1016 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | BETAMETHASONE DIPROPIONATE USP, 0.05% | 6 | 0.2857 |
| 1 | TALIMOGENE LAHERPAREPVEC | 60 | 0.0378 |
| 2 | PANITUMUMAB | 480 | 0.0298 |
| 3 | ANTI-INHIBITOR COAGULANT COMPLEX | 32 | 0.0290 |
| 4 | DIFLUPREDNATE | 105 | 0.0272 |
| 5 | MOSUNETUZUMAB | 29 | 0.0262 |
| 6 | PLATINUM | 13 | 0.0245 |
| 7 | DINUTUXIMAB | 18 | 0.0210 |
| 8 | CARFILZOMIB | 558 | 0.0197 |
| 9 | SOTORASIB | 68 | 0.0196 |
| # | Drug class | Count |
|---|---|---|
| 0 | Corticosteroid [EPC] | 4226 |
| 1 | Platinum-based Drug [EPC] | 2974 |
| 2 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2426 |
| 3 | Alkylating Drug [EPC] | 2039 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 1576 |
| 5 | CD20-directed Cytolytic Antibody [EPC] | 1466 |
| 6 | Folate Analog Metabolic Inhibitor [EPC] | 1379 |
| 7 | Kinase Inhibitor [EPC] | 1276 |
| 8 | Microtubule Inhibitor [EPC] | 1187 |
| 9 | Proteasome Inhibitor [EPC] | 1009 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | CD38-directed Cytolytic Antibody [EPC] | 327 | 0.0559 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 2426 | 0.0246 |
| 2 | Interleukin-5 Antagonist [EPC] | 14 | 0.0203 |
| 3 | Glycolipid Disialoganglioside-directed Antibody [EPC] | 18 | 0.0166 |
| 4 | Oxaborole Antifungal [EPC] | 1 | 0.0143 |
| 5 | Topoisomerase Inhibitor [EPC] | 906 | 0.0118 |
| 6 | Chemokine Receptor Type 4 Interaction [EPC] | 16 | 0.0118 |
| 7 | Epidermal Growth Factor Receptor Antagonist [EPC] | 531 | 0.0112 |
| 8 | Platinum-based Drug [EPC] | 2974 | 0.0109 |
| 9 | Recombinant Human Nerve Growth Factor [EPC] | 135 | 0.0100 |